Adverse Reactions

In the combined studies of GEMINI I and II the adverse reactions that occurred in ≥5% were nausea, nasopharyngitis, upper respiratory tract infection, arthralgia, pyrexia, fatigue, headache, cough. Infusion-related reactions were reported in 4% of patients receiving vedolizumab. You can reference the table for the list of adverse reactions. 

.pdfAdverse reactionsView full adverse reactions table (tables from SmPC)